Navigation Links
Nottingham leads £2.6m international clinical trial into new stroke treatment
Date:3/18/2013

Scientists in Nottingham are leading an international study to investigate the effectiveness of a new treatment on a devastating type of stroke.

The team at The University of Nottingham has been awarded 2.6 million by the National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme to lead the clinical trial into the use of the drug tranexamic acid in people who have suffered an intracerebral haemorrhage, a type of stroke caused by bleeding in the brain.

Leading the trial, Dr Nikola Sprigg in the University's Division of Stroke, said: "This is potentially very exciting this drug could offer new hope for a condition for which there is currently no effective treatment.

"If successful, it could potentially improve the lives of thousands of people with haemorrhagic stroke, preventing deaths and reducing disability to increase their chances of leading a full and independent life."

Around 150,000 people in the UK suffer a stroke every year the majority of these are ischaemic strokes caused by a blocked blood vessel on the brain which can be treated very successfully in many cases with the use of clot-busting drugs (thrombolysis) administered within 4.5 hours of the stroke.

However, 15 per cent of all strokes affecting around 22,000 people every year are caused by haemorrhagic stroke when a blood vessel in the brain bursts, leading to permanent damage. Whilst all people with acute stroke benefit from treatment on a stroke unit, there is currently no specific treatment for haemorrhagic stroke and unfortunately many people affected will die within a few days. Those who do survive are often left with debilitating disabilities including paralysis and an inability to speak.

The four-year study will recruit around 2,000 people from 120 hospitals and stroke units, initially across the UK and then worldwide these will be people who come into hospital as an emergency after suffering from a suspected stroke.

It follows a small pilot study last year, funded by The University of Nottingham and charity the Stroke Association, which concluded that a larger study was needed to accurately assess the effectiveness of the drug tranexamic acid. The drug was chosen for the study after previous research showed that it was successful in stopping bleeding in people involved in road traffic accidents.

For the latest trial, people who are diagnosed as having had bleeding on the brain confirmed by CT scan will be offered the chance to take part in the study. Where the person is too ill to decide, permission will be asked of their family.

Half of those who sign up will be given the drug within eight hours of their stroke while half will receive a placebo. The patient's progress will be carefully monitored in hospital over the course of the next seven days and they will receive a second CT scan to see whether the amount of blood on the brain has increased.

The study team will then follow up with the person after three months to assess their recovery, level of disability and how independent they are following their stroke.

The rationale behind giving the treatment so quickly (less than eight hours after stroke onset), is in an attempt to reduce the risk of continued bleeding, therefore potentially reducing the amount of permanent brain damage caused.

The Division of Stroke and Nottingham Stroke Trials Unit, based at Nottingham University Hospitals NHS Trust's City Hospital campus, has an international reputation for clinical and laboratory research in stroke. It also works closely with NHS colleagues in running the nationally-acclaimed clinical stroke service at the hospital.

Recruitment starts this week, initially at 30 UK centres including Nottingham, with further centres across the UK and worldwide expected to join the study in coming months.


'/>"/>

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Nottingham expertise in major European drug discovery partnership
2. Research leads to better understanding of peripheral neuropathy
3. Manchester leads new international study investigating Inflammatory Bowl Disease
4. Premium Astrology Client Care Team Leads Norah Guide to New Reviews Daily
5. Inhaled betadine leads to rare complication
6. Platypus Australia Leads The Way For Summer Fashion By Launching New Range of Children’s UV Protective Swimwear
7. Frog-in-bucket-of-milk folklore leads to potential new antibiotics
8. University of Cincinnati leads first trial on steroid and CNI withdrawal post-transplant
9. Decreased kidney function leads to decreased cognitive functioning
10. Childhood abuse leads to poor adult health
11. Healthy outlook leads to a healthy lifestyle: study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... CO (PRWEB) , ... April 25, 2017 , ... ... and Liberty attempts to compare student test score performance for the 2015-16 school ... of the state’s voucher programs. Though it highlights important patterns in student test ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: